“The wake-up call happened during COVID — we realized our dependency on basic medicines coming from outside Europe was dangerously high.” Elisabeth Stampa, CEO of Medichem and Vice President of Medicines for Europe, has been one of the pharmaceutical industry’s
“The role of CDMOs is already critical — and this level of ambiguity makes it all the more critical.” Ryan Kelly, Interim CEO of Rx-360, has spent years helping pharmaceutical manufacturers and their supply chain partners prepare for the unexpected.
“83% of the top 100 most prescribed generic medicines in the US have no domestic manufacturing source for their API.” — Charles Lyon, VP Manufacturing, Procurement & Logistics, API Innovation Center And yet the capacity to produce these drug products
“Managing a radiopharmaceutical supply chain is like transporting a block of ice in the middle of summer under the scorching sun in the desert—you have no means to protect it or cover it, so it just continues melting.” Daniel Rossetto,
On February 20, the U.S. Supreme Court delivered one of the most consequential trade rulings in decades. In a 6–3 decision, the justices held that President Trump had no authority under the International Emergency Economic Powers Act (IEEPA) to impose
“Intrinsically, there is nothing wrong with using Chinese CDMOs. But because of geopolitical issues, some large pharma want to have redundancy of that supply chain in the US.” Dr. Reza Oliyai, President and CEO of Oliyai Consulting Corporation, spent 28
The pharma manufacturing landscape in 2026 is more volatile than ever. Take part in this benchmarking study to see how your peers are responding. Rapidly changing geopolitics. Capacity constraints. Pricing pressure. Technology disruption. The challenges facing biopharma sponsors and CDMO
FDA hemorrhaging staff while promising to fast-track advanced modalities. BIOSECURE Act signed into law with five-year phase-out timelines. Tariffs creating 50% cost increases on manufacturing equipment. Most Favored Nation deals cutting prices. Cell and gene therapy facilities closing despite scientific
EXCLUSIVE DOWNLOAD Reshoring Pressure Meets Manufacturing Reality Download this report from External Manufacturing Leaders Boston for candid insights into how US Pharma and Biotech executives are navigating external manufacturing in 2026 In January 2026, senior external manufacturing executives from major pharmaceutical
Alliance for Regenerative Medicine’s State of the Industry briefing at JP Morgan Healthcare Conference signals cautious optimism backed by $11.1B in 2025 funding The cell and gene therapy (CGT) sector attracted $11.1 billion in investment across 216 financings in 2025—representing
